Microbiological aspects of rifapentine

Drugs of Today

Volumn 35, Issue SUPPL. D, 1999, Pages 7-15

  Heifets, Leonid ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; RIFAPENTINE;

ANTIMICROBIAL ACTIVITY; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RELEASE; DRUG SENSITIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS;

EID: 0033460250     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Cricchio, R., Arioli, V., Lancini, G.C. Hydrazones of 3-formylrifamycin SV. I. Hydrazones with N-amino-N'-substituted piperazines: Synthesis, antibacterial activity and other biological properties. II Farmaco 1975, 30: 607-19.
2. Arioli, V., Berti, M., Carniti, G., Randisi, E., Rossi, E., Scotti, R. Antibacterial activity of DL473, a new semisynthetic rifamycin derivative. J Antibiot (Tokyo) 1981, 34: 1026-29.
3. Ridgway, G.L., Oriel, J.D. Activity of antimicrobials against Chlamydia trachomatis in vitro. J Antimicrob Chemother 1979, 5: 483-4.
4. Pattyn, S.R. Rifabutin and rifapentine compared with rifampin against Mycobacterium leprae in mice. Antimicrob Agents Chemother 1987, 31: 134.
5. Schulin, T., Wennersten, C.B., Ferraro, M.J., Moellering, J., R.C., Ekiopoulos, G.M. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998, 42: 1520-3.
6. Hoppe, J.E., Bryskier, A. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother 1998, 42: 965-6.
7. Yee, Y.C., Kisslinger, B., Yu, V.L., Jin, D.J. A mechanism of rifamycin inhibition and resistance in Pseudomonas aeruginosa. J Antimicrob Chemother 1996, 38: 133-7.
8. Araujo, F.G., Khan, A.A., Remington, J.S. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob Agents Chemother 1996, 40: 1335-7.
9. García-Rodríguez, J.A., Muñoz-Bellido, J.L., Fresnadillo, M.J., Trujillano, I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother 1993, 37: 911-3.
10. Varaldo, P.E., Debbia, E., Schito, G.C. In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species. Antimicrob Agents Chemother 1985, 27: 615-8.
11. Jones, R.B., Ridgway, G.L., Boulding, S., Hunley, K.L. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis, Rev Infect Dis 1983, 5(Suppl. 3): S556-61.
12. Soriano, F., Fernández-Roblas, R., Calvo, R., García-Calvo, G. In vitro susceptibilities of aerobic and facultative non-spore-forming Gram-positive bacilli to HMR 3647 (RU66647) and 14 other antimicrobials. Antimicrob Agents Chemother 1998, 42: 1028-33.
13. Dhillon, J., Dickinson, J.M., Gay, A.J., Ng, T.K., Mitchison, D.A. Activity of two long lasting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber Lung Dis 1992, 73: 116-23.
14. Truffot-Pernot, C.H., Grosset, J., Bismuth, R., Lecoeur, H.L. Activité de la rifapicine administrée de maniére intermittente et de la cyclopentyl rifamycine (ou DL473) sur la tuberculose expérimentale de la souris. Rev Fr Mal Respir 1983, 11: 875-82.
15. Ji, B., Truffot-Pernot, C., Lacroix, C. et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993, 148: 1541-6.
16. Yates, M.D., Collins, C.H. Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifampicin. J Antimicrob Chemother 1982, 10: 147-50.
17. Tsukamura, M., Mizuno, S., Toyama, H. In vitro antimycobacterial activity of rifapentine (comparison with rifampicin). Kekkaku 1986, 61: 633-9.
18. Dickinson, J.M., Mitchison, D.A. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987, 68: 177-82.
19. Dickinson, J.M., Mitchison, D.A. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987, 68: 113-9.
20. Dickinson, J.M., Mitchison, D.A. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle 1987, 68: 183-93.
21. Heifets, L.B., Lindholm-Levy, P.J., Flory, M.A. Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am Rev Respir Dis 1990, 141: 626-30.
22. Mor, N., Simon, B., Mezo, N., Heifets, L. Comparison of the activities of rifapentine and rifampin against M. tuberculosis residing in human macrophages. Antimicrob Agents Chemother 1995, 39: 2073-7.
23. Heifets, L., Sanchez, T., Vanderkolk, J., Pham, V. Development of rifapentine susceptibility tests for Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999, 43: 25-8.
24. Easmon, C.S.F, Crane, JP. Comparative uptake of rifampicin and rifapentine (DL473) by human neutrophils. J Antimicrob Chemother 1984, 13: 585-91.
25. Pascual, A., Tsukayama, D., Kovarik, J., Gekker, G., Peterson, P. Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes. Eur J Clin Microbiol 1987, 6: 152-7.
26. Hoger, P.H., Vosbeck, K., Seger, R., Hitzig, W.H. Uptake, intracellular activity, and influence of rifampin on normal function of polymorphonuclear leukocytes. Antimicrob Agents Chemother 1985, 28: 667-74.
27. Prokesch, R.C., Hand, W.L Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1982, 21: 373-80.
28. Dhillon, J., Mitchison, J.A. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis 1992, 145: 212-4.
29. Hand, W.L., Corwin, R.W., Steinberg, T.H., Grossman, G.D. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis 1984, 129: 933-7.
30. Cynamon, M.H. Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare. Antimicrob Agents Chemother 1985, 28: 440.
31. Bermudez, L.E., Wu, M., Young, L.S., Inderlied, C.B. Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex. J Infect Dis 1992, 166: 923-6.
32. Crowle, A.J., Elkins, N., May, M.H. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis 1988, 137: 1141-6.
33. Bermudez, L.E.M., Wu, M., Young, L.S. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin. J Infect Dis 1987, 156: 510-3.
34. Casal, R.M., Rodríguez-López, F., Villalba-Montoro, R., González-Requero, A.I. In vitro activity of clofazimine alone and in combination with amikacin, roxithromycin, rifampicin and rifapentine against Mycobacterium avium-intracellulare. Enferm Infect Microbiol Clin 1989, 7: 432-5.
35. Musser, J. M. Antimicrobial agent resistance in mycobacteria: Molecular genetic insights. Clin Microbiol Rev 1995, 8: 496-514.
36. Telenti, A., Imboden, P., Marchesi, F. et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341: 647-50.
37. Williams, D.L., Waguespack, C., Eisenach, K. et al. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994, 38: 2380-6.
38. Williams, D.L., Spring, L., Collins, L. et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42: 1853-7.